Gregorio Marañon Hospital
Madrid, 28007, Spain
Completed
NCT Number: NCT04416594
Impact of Acquired FXIII Deficiency on Morbidity and Mortality
Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality
Completed
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- FXIII levels < 70%
Exclusion criteria
- None
Treatment and study plan
Data Collection
OtherOnly data collection
Primary outcomes
-
Cut-Point levels of FXIII
Time frame: 2 years
The investigators aim to find a laboratory parameter, a cut-point plasma level of FXIII, to identify an increased in morbidity and mortality in a mixed cohort of hospitalized patients
Sponsors and collaborators
Lead sponsor
Patricia Duque González
Other
Registry information
Official study title
Impact of Acquired FXIII Deficiency on Morbidity and Mortality Among Hospitalized Patients
Important dates
- Study start
- 2019
- Primary completion
- 2020
- Study completion
- 2020
- First posted
- Jun 4, 2020
- Registry last updated
- Jun 5, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.